Developer docs
API playgroundTry for free, no card

Search company profiles

Huons

Full company profile

uuid0002as5

Namestring
Huons
Legal namestring
(주)휴온스
Websiteurl
huons.com
Company typeenum
Public
Founded yearint
1965
Descriptiontext

Huons is a KOSDAQ-listed South Korean pharmaceutical company headquartered in Seongnam (Gyeonggi Province), operating as the core operating subsidiary of Huons Global following a 2016 holding company restructuring. Founded in 1965 as Gwangmyeong Pharmaceutical Industry, the company runs two GMP-compliant manufacturing facilities in Jecheon Bio Valley for sterile injectables, ophthalmic, and oral formulations, plus the Huons Dongam R&D Center in Gwacheon (completed November 2024). Through its subsidiary network, Huons spans prescription pharmaceuticals (diabetes, cardiovascular, anesthesia/pain, dermatology), OTC products (Nizoral antifungal, Menolacto probiotic), medical devices (DIA:CONN P8 Bluetooth smart insulin pen, Dermashine Duo RF aesthetic device, Elravie dermal fillers, Premium 9Pin Needle), biopharmaceutical CDMO via the December 2024 PanGen Biotech acquisition, and vaccine distribution via a 2026 Sanofi Korea partnership.

The product portfolio rests on proprietary technology including Korea's first plastic container syringe (Patent No. 0381404, 1998), a nano-composite ophthalmic solution patented across Japan, six European countries, Russia, and Saudi Arabia, and the peptide-based HUC1-394 dry eye candidate licensed from Novacell Technology, which received Phase 2 IND approval in March 2026. FDA approvals cover lidocaine (1% and 2%) and saline injections, enabling US exports, though a June 2026 FDA warning letter for smoke study deficiencies and prior Q1 2026 export detention have created regulatory headwinds.

Huons earns revenue through prescription drug sales via hospital, pharmacy, and CSO networks (largely under Korean National Health Insurance reimbursement), direct-to-consumer online sales through huonsmall.com and Naver Brand Stores for non-reimbursed devices like DIA:CONN P8, international exports through Huons USA/Japan and regional distributors, contract manufacturing, and the new Sanofi vaccine distribution channel. Q1 2026 consolidated revenue was KRW 141.9 billion (~USD 94.9 million), down 2.7% YoY, with an operating loss of KRW 649 million driven by US recall warranty costs (KRW 1.07 billion), FDA export detention, and softer contract manufacturing demand.

Short descriptiontext

Huons is a South Korean KOSDAQ-listed pharmaceutical manufacturer producing prescription drugs, OTC brands, medical devices, and biopharmaceutical CDMO services for patients, hospitals, and global pharma clients across Korea, the US, Japan, and China.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSeongnam, South Korea
HQ citystring
Seongnam
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
prescription pharmaceuticals, sterile injectables, medical devices, contract manufacturing, health supplements
Industry1 code
SECONDARYIMALAIAE
Parenteral & Injectable Packaging Components (Stoppers, Seals, Syringes, Cartridges)
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Surgical and Medical Instrument Manufacturing339112
  • Surgical Appliance and Supplies Manufacturing339113
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Surgical & Medical Instruments & Apparatus3841
Product category
Pharmaceutical Manufacturing
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Pharmaceutical Products
TypeOne Time License
Description

Revenue from prescription drugs (specialist pharmaceuticals), OTC products, and anesthetic agents sold through pharmaceutical distribution networks, hospitals, and pharmacies. Includes injectable, oral, and topical formulations across therapeutic categories.

koreabiomed.com
2Medical Devices
TypeOne Time License
Description

Revenue from medical devices including smart insulin pens (DIA:CONN P8), aesthetic devices (Dermashine Duo RF, Premium 9Pin Needle), and other medical equipment sold directly and through distributors.

huons.com
3Vaccine Distribution
TypeProfessional Services
Description

Revenue from distribution and co-promotion of five Sanofi vaccines including influenza, hepatitis A, meningococcal, and adult vaccines through Huons' nationwide logistics and sales network in Korea.

koreatimes.co.kr
4Contract Manufacturing
TypeProfessional Services
Description

Revenue from contract manufacturing services for solid oral dosage forms and injectable products for pharmaceutical clients, including FDA-approved manufacturing capabilities.

huons.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1DIA:CONN P8 Smart Insulin Pen - 31% price reduction
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Reduced from 550,000 KRW to 380,000 KRW effective November 1, 2025 to improve accessibility for Type 2 and some Type 1 diabetes patients not eligible for National Health Insurance reimbursement.

huons.com
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1Nizoral (니조랄)
Description

Antifungal shampoo and topical solution for dandruff, seborrheic dermatitis, and tinea versicolor treatment

huons.com
+5 more records
Core offering1 text field

Huons manufactures and distributes a diversified portfolio of pharmaceutical products spanning sterile injectables, topical solutions, oral dosage forms, anesthetics, OTC products, and medical devices including the DIA:CONN P8 Bluetooth smart insulin pen and aesthetic devices. The company also operates contract manufacturing services for solid oral and injectable pharmaceutical products, holds exclusive Korean distribution rights for the Nizoral antifungal brand, and distributes Sanofi vaccines through a nationwide Korean logistics network.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Users of DIA:CONN P8 smart insulin pen achieved 11% greater Time In Range compared to traditional insulin pen users
+2 more records
Product and service12 records
1DIA:CONN P8 Smart Insulin Pen
CategoryMedical Devices
Description

Bluetooth-connected smart insulin pen with data tracking for diabetes patients; clinical study showed 11% greater Time In Range compared to traditional insulin pen users

2Nizoral 2% Solution (Ketoconazole)
CategoryOTC Pharmaceuticals
Description

Topical antifungal shampoo and solution for dandruff, seborrheic dermatitis, and tinea versicolor treatment; OTC consumer product used globally for over 30 years

3Dermashine Duo RF
CategoryMedical Devices
Description

Hybrid medical device combining drug delivery with radiofrequency technology for facial aesthetic treatments, marketed through subsidiary Huons Meditech

4Premium 9Pin Needle
CategoryMedical Devices
Description

Aesthetic medical device needle for cosmetic procedures with China NMPA approval

5Lidocaine Injection Products
CategoryPrescription Pharmaceuticals
Description

Local anesthetic injectable products including 1% lidocaine 5mL vials, 0.75% bupivacaine HCl, and 2% lidocaine with FDA approvals for US market

6Saline Injection Products
CategoryPrescription Pharmaceuticals
Description

Sterile saline injections for medical use with FDA 510K approval for US market

7HUC1-394 Dry Eye Treatment
CategoryPrescription Pharmaceuticals
Description

Pipeline peptide-based ophthalmic solution for dry eye disease with novel inflammation-resolution mechanism distinct from conventional suppressive approaches; licensed from Novacell Technology

8Contract Manufacturing Services
CategoryContract Manufacturing
Description

Contract manufacturing services for solid oral dosage forms and injectable products for pharmaceutical clients, including FDA-approved manufacturing capabilities

9Sanofi Vaccine Distribution
CategoryVaccine Distribution
Description

Nationwide Korean distribution and co-promotion of five Sanofi vaccines including influenza, hepatitis A, meningococcal, and adult vaccines through Huons' logistics and sales network

10Menolacto Probiotic Supplement
CategoryHealth Supplements
Description

Women's menopause probiotic health supplement exceeding 100 billion KRW in cumulative sales

11Hugtoksi Botulinum Toxin
CategoryAesthetic Pharmaceuticals
Description

Botulinum toxin product registered in Iraq for aesthetic/therapeutic use

12Biopharmaceutical CDMO Services
CategoryContract Manufacturing
Description

Biopharmaceutical CDMO services leveraging proprietary PANGEN CHO-TECH platform through subsidiary PanGen Biotech, with 41 production cell lines including biosimilars in development for major reference products

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Huonslab
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-01
Description

Huons Global announced plans to proceed with a merger between its affiliates Huons and Huonslab to secure long-term growth and fund its biotech unit, addressing Huonslab's capital impairment and inability to raise funds independently while leveraging Huons' manufacturing and development capabilities.

koreabiomed.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-03-25
Description

Huons signed a distribution and co-promotion agreement with Sanofi Korea to enter the domestic vaccine market starting April 1, 2026. Huons handles nationwide distribution and marketing of five vaccines developed by Sanofi including influenza, hepatitis A, meningococcal, and adult vaccines, leveraging Huons' logistics and sales network to expand vaccine access in Korea.

Strategic tierCoreTypeOthersAnnounced on2025-12-01
Description

Huons Meditech, a subsidiary of Huons Group, launched Dermashine Duo RF hybrid medical device combining drug delivery with radiofrequency technology for facial aesthetic treatments.

Strategic tierCoreTypeOthersAnnounced on2025-01-01
Description

PanGen Biotech, a subsidiary of Huons Group acquired in December 2024, leverages its proprietary PANGEN CHO-TECH platform for biopharmaceutical CDMO services, holding 41 production cell lines including biosimilars in development for BMS' Yervoy, J&J's Tremfya, and Amgen's Evenity.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-08-01
Description

Huons entered a technology licensing agreement with Novacell Technology for the dry eye treatment candidate HUC1-394, a peptide-based ophthalmic solution. Huons received Phase 1 IND approval in January 2024 and Phase 2 IND approval in March 2026 for clinical trials.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

KOSDAQ-listed Korean pharmaceutical company with a similarly diversified portfolio across prescription drugs, OTC, specialty injectables, and medical devices. Comparable in size, manufacturing footprint, and channel strategy via CSO networks and domestic hospital/pharmacy distribution.

TypeDirect peer
Description

Korean pharma manufacturer with overlapping therapeutic categories (anesthesia, dermatology, gastrointestinal) and direct-to-consumer health supplement brands. Both operate FDA-approved facilities and export injectable and finished dosage products.

TypeDirect peer
Description

Korean pharmaceutical manufacturer with broad prescription and OTC portfolio, FDA-approved manufacturing, and international distribution. Similar scale and channel mix including CSO distribution and direct pharmacy supply.

TypeBroad incumbent
Description

Larger Korean biopharma with a major biosimilar franchise. Comparable through PanGen Biotech's biosimilar CDMO platform and the broader Huons Group's biologics ambitions via Huonslab and PanGen.

TypeDirect peer
Description

Korean vaccine and biopharmaceutical manufacturer. Directly comparable now that Huons has entered the domestic vaccine market via Sanofi Korea distribution, leveraging overlapping customers and regulatory expertise.

6LG Chem Life Sciences
TypeBroad incumbent
Description

Diversified Korean chemical/pharmaceutical company with prescription drugs, vaccines, and biologics. Comparable as a domestic competitor across injectables, ophthalmology, and CDMO adjacencies.

TypeDirect peer
Description

Mid-sized Korean pharmaceutical company with a comparable focus on specialty prescription drugs and CNS/dermatology categories. Operates similar hospital- and pharmacy-channel distribution via CSO networks in Korea.

TypeDirect peer
Description

Pure-play insulin pen and injection device manufacturer. Directly comparable to Huons' DIA:CONN P8 smart insulin pen business as a global competitor in connected diabetes delivery devices.

TypeOthers
Description

Holding company and direct parent of Huons. Listed on KOSDAQ, captures consolidated value of Huons plus subsidiaries (Humedix, Huons BioPharma, PanGen, Huons Meditech, Huonslab). Relevant for understanding group-level financials and the pending Huons/Huonslab merger.

TypeBroad incumbent
Description

Global leader in insulin pens (NovoPen) and GLP-1 therapies. Sets the competitive benchmark for DIA:CONN P8 in connected insulin delivery and for Huons' broader diabetes portfolio.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries12 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment12 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Huons

Pharmaceutical Manufacturinghuons.com

Huons is a South Korean KOSDAQ-listed pharmaceutical manufacturer producing prescription drugs, OTC brands, medical devices, and biopharmaceutical CDMO services for patients, hospitals, and global pharma clients across Korea, the US, Japan, and China.

What Huons does

Huons is a KOSDAQ-listed South Korean pharmaceutical company headquartered in Seongnam (Gyeonggi Province), operating as the core operating subsidiary of Huons Global following a 2016 holding company restructuring. Founded in 1965 as Gwangmyeong Pharmaceutical Industry, the company runs two GMP-compliant manufacturing facilities in Jecheon Bio Valley for sterile injectables, ophthalmic, and oral formulations, plus the Huons Dongam R&D Center in Gwacheon (completed November 2024). Through its subsidiary network, Huons spans prescription pharmaceuticals (diabetes, cardiovascular, anesthesia/pain, dermatology), OTC products (Nizoral antifungal, Menolacto probiotic), medical devices (DIA:CONN P8 Bluetooth smart insulin pen, Dermashine Duo RF aesthetic device, Elravie dermal fillers, Premium 9Pin Needle), biopharmaceutical CDMO via the December 2024 PanGen Biotech acquisition, and vaccine distribution via a 2026 Sanofi Korea partnership.

The product portfolio rests on proprietary technology including Korea's first plastic container syringe (Patent No. 0381404, 1998), a nano-composite ophthalmic solution patented across Japan, six European countries, Russia, and Saudi Arabia, and the peptide-based HUC1-394 dry eye candidate licensed from Novacell Technology, which received Phase 2 IND approval in March 2026. FDA approvals cover lidocaine (1% and 2%) and saline injections, enabling US exports, though a June 2026 FDA warning letter for smoke study deficiencies and prior Q1 2026 export detention have created regulatory headwinds.

Huons earns revenue through prescription drug sales via hospital, pharmacy, and CSO networks (largely under Korean National Health Insurance reimbursement), direct-to-consumer online sales through huonsmall.com and Naver Brand Stores for non-reimbursed devices like DIA:CONN P8, international exports through Huons USA/Japan and regional distributors, contract manufacturing, and the new Sanofi vaccine distribution channel. Q1 2026 consolidated revenue was KRW 141.9 billion (~USD 94.9 million), down 2.7% YoY, with an operating loss of KRW 649 million driven by US recall warranty costs (KRW 1.07 billion), FDA export detention, and softer contract manufacturing demand.

Huons firmographics

Firmographics
Name
Huons
Legal name
(주)휴온스
Website
https://huons.com
Company type
Public
Founded year
1965
Operating status
Operating
Headcount range
101–250 employees
Short description
Huons is a South Korean KOSDAQ-listed pharmaceutical manufacturer producing prescription drugs, OTC brands, medical devices, and biopharmaceutical CDMO services for patients, hospitals, and global pharma clients across Korea, the US, Japan, and China.
Ownership category
akta.pro rank

Where Huons is headquartered

Location

Headquarters

HQ city
Seongnam
HQ country
South Korea
HQ region
Asia

Offices4 records

Markets served

Huons business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Products: Revenue from prescription drugs (specialist pharmaceuticals), OTC products, and anesthetic agents sold through pharmaceutical distribution networks, hospitals, and pharmacies. Includes injectable, oral, and topical formulations across therapeutic categories.
  2. Medical Devices: Revenue from medical devices including smart insulin pens (DIA:CONN P8), aesthetic devices (Dermashine Duo RF, Premium 9Pin Needle), and other medical equipment sold directly and through distributors.
  3. Vaccine Distribution: Revenue from distribution and co-promotion of five Sanofi vaccines including influenza, hepatitis A, meningococcal, and adult vaccines through Huons' nationwide logistics and sales network in Korea.
  4. Contract Manufacturing: Revenue from contract manufacturing services for solid oral dosage forms and injectable products for pharmaceutical clients, including FDA-approved manufacturing capabilities.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goDIA:CONN P8 Smart Insulin Pen - 31% price reduction

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

Huons product offering

Product offering

Core offering

Huons manufactures and distributes a diversified portfolio of pharmaceutical products spanning sterile injectables, topical solutions, oral dosage forms, anesthetics, OTC products, and medical devices including the DIA:CONN P8 Bluetooth smart insulin pen and aesthetic devices. The company also operates contract manufacturing services for solid oral and injectable pharmaceutical products, holds exclusive Korean distribution rights for the Nizoral antifungal brand, and distributes Sanofi vaccines through a nationwide Korean logistics network.

Differentiator

Problem solved

Functional benefit

Brands

  • Nizoral (니조랄): Antifungal shampoo and topical solution for dandruff, seborrheic dermatitis, and tinea versicolor treatment
  • Menolacto (메노락토)
  • DIA:CONN P8
  • Elravie (엘라비에)
  • Alloon (알룬)
  • Veraderm (베러덤)

Products and services

  • DIA:CONN P8 Smart Insulin Pen Bluetooth-connected smart insulin pen with data tracking for diabetes patients; clinical study showed 11% greater Time In Range compared to traditional insulin pen users
  • Nizoral 2% Solution (Ketoconazole) Topical antifungal shampoo and solution for dandruff, seborrheic dermatitis, and tinea versicolor treatment; OTC consumer product used globally for over 30 years
  • Dermashine Duo RF Hybrid medical device combining drug delivery with radiofrequency technology for facial aesthetic treatments, marketed through subsidiary Huons Meditech
  • Premium 9Pin Needle Aesthetic medical device needle for cosmetic procedures with China NMPA approval
  • Lidocaine Injection Products Local anesthetic injectable products including 1% lidocaine 5mL vials, 0.75% bupivacaine HCl, and 2% lidocaine with FDA approvals for US market
  • Saline Injection Products Sterile saline injections for medical use with FDA 510K approval for US market
  • HUC1-394 Dry Eye Treatment Pipeline peptide-based ophthalmic solution for dry eye disease with novel inflammation-resolution mechanism distinct from conventional suppressive approaches; licensed from Novacell Technology
  • Contract Manufacturing Services Contract manufacturing services for solid oral dosage forms and injectable products for pharmaceutical clients, including FDA-approved manufacturing capabilities
  • Sanofi Vaccine Distribution Nationwide Korean distribution and co-promotion of five Sanofi vaccines including influenza, hepatitis A, meningococcal, and adult vaccines through Huons' logistics and sales network
  • Menolacto Probiotic Supplement Women's menopause probiotic health supplement exceeding 100 billion KRW in cumulative sales
  • Hugtoksi Botulinum Toxin Botulinum toxin product registered in Iraq for aesthetic/therapeutic use
  • Biopharmaceutical CDMO Services Biopharmaceutical CDMO services leveraging proprietary PANGEN CHO-TECH platform through subsidiary PanGen Biotech, with 41 production cell lines including biosimilars in development for major reference products

Quantifiable outcome

  • Users of DIA:CONN P8 smart insulin pen achieved 11% greater Time In Range compared to traditional insulin pen users
  • +2 more outcomes

Companies that use Huons

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Huons technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Huons partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • HuonslabcoreStrategic or Co-development Partner · 1 May 2026Huons Global announced plans to proceed with a merger between its affiliates Huons and Huonslab to secure long-term growth and fund its biotech unit, addressing Huonslab's capital impairment and inability to raise funds independently while leveraging Huons' manufacturing and development capabilities.
  • Sanofi KoreacoreChannel Partner/ Reseller/ Distributor · 25 March 2026Huons signed a distribution and co-promotion agreement with Sanofi Korea to enter the domestic vaccine market starting April 1, 2026. Huons handles nationwide distribution and marketing of five vaccines developed by Sanofi including influenza, hepatitis A, meningococcal, and adult vaccines, leveraging Huons' logistics and sales network to expand vaccine access in Korea.
  • Huons Meditech (Subsidiary)coreOthers · 1 December 2025Huons Meditech, a subsidiary of Huons Group, launched Dermashine Duo RF hybrid medical device combining drug delivery with radiofrequency technology for facial aesthetic treatments.
  • PanGen Biotech (Subsidiary)coreOthers · 1 January 2025PanGen Biotech, a subsidiary of Huons Group acquired in December 2024, leverages its proprietary PANGEN CHO-TECH platform for biopharmaceutical CDMO services, holding 41 production cell lines including biosimilars in development for BMS' Yervoy, J&J's Tremfya, and Amgen's Evenity.
  • Novacell TechnologycoreStrategic or Co-development Partner · 1 August 2020Huons entered a technology licensing agreement with Novacell Technology for the dry eye treatment candidate HUC1-394, a peptide-based ophthalmic solution. Huons received Phase 1 IND approval in January 2024 and Phase 2 IND approval in March 2026 for clinical trials.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Huons competitors and assessment

Company assessment

Direct peers

  • Hanmi Pharmaceutical: KOSDAQ-listed Korean pharmaceutical company with a similarly diversified portfolio across prescription drugs, OTC, specialty injectables, and medical devices. Comparable in size, manufacturing footprint, and channel strategy via CSO networks and domestic hospital/pharmacy distribution.
  • Daewoong Pharmaceutical: Korean pharma manufacturer with overlapping therapeutic categories (anesthesia, dermatology, gastrointestinal) and direct-to-consumer health supplement brands. Both operate FDA-approved facilities and export injectable and finished dosage products.
  • Yuhan Corporation: Korean pharmaceutical manufacturer with broad prescription and OTC portfolio, FDA-approved manufacturing, and international distribution. Similar scale and channel mix including CSO distribution and direct pharmacy supply.
  • SK Bioscience: Korean vaccine and biopharmaceutical manufacturer. Directly comparable now that Huons has entered the domestic vaccine market via Sanofi Korea distribution, leveraging overlapping customers and regulatory expertise.
  • Bukwang Pharmaceutical: Mid-sized Korean pharmaceutical company with a comparable focus on specialty prescription drugs and CNS/dermatology categories. Operates similar hospital- and pharmacy-channel distribution via CSO networks in Korea.
  • Embecta (Becton Dickinson spin-off): Pure-play insulin pen and injection device manufacturer. Directly comparable to Huons' DIA:CONN P8 smart insulin pen business as a global competitor in connected diabetes delivery devices.

Broad incumbents

  • Celltrion: Larger Korean biopharma with a major biosimilar franchise. Comparable through PanGen Biotech's biosimilar CDMO platform and the broader Huons Group's biologics ambitions via Huonslab and PanGen.
  • LG Chem Life Sciences: Diversified Korean chemical/pharmaceutical company with prescription drugs, vaccines, and biologics. Comparable as a domestic competitor across injectables, ophthalmology, and CDMO adjacencies.
  • Novo Nordisk: Global leader in insulin pens (NovoPen) and GLP-1 therapies. Sets the competitive benchmark for DIA:CONN P8 in connected insulin delivery and for Huons' broader diabetes portfolio.

Others

  • Huons Global (parent): Holding company and direct parent of Huons. Listed on KOSDAQ, captures consolidated value of Huons plus subsidiaries (Humedix, Huons BioPharma, PanGen, Huons Meditech, Huonslab). Relevant for understanding group-level financials and the pending Huons/Huonslab merger.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Huons social profiles

Digital presence

Huons financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Huons leadership team

Management profile

Number of profiles

Profiles2 records

Huons subsidiaries and ownership

Company hierarchy

Subsidiaries12 records

Huons funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Huons M&A and investment

M&A and investment

M&A1 record

Investments12 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Huons

What does Huons do?

Huons manufactures and distributes a diversified portfolio of pharmaceutical products spanning sterile injectables, topical solutions, oral dosage forms, anesthetics, OTC products, and medical devices including the DIA:CONN P8 Bluetooth smart insulin pen and aesthetic devices. The company also operates contract manufacturing services for solid oral and injectable pharmaceutical products, holds exclusive Korean distribution rights for the Nizoral antifungal brand, and distributes Sanofi vaccines through a nationwide Korean logistics network.

Is Huons a public or private company?

Huons is a public company. It is classified as public and is currently operating.

When was Huons founded?

Huons was founded in 1965. It employs 101 to 250 people.

Where is Huons based?

Huons is headquartered in Seongnam, South Korea, in the Asia region.

How does Huons make money?

Four revenue lines are on record. Pharmaceutical Products are the primary driver. The others are medical Devices, vaccine Distribution and contract Manufacturing.

Who are Huons's main competitors?

Direct peers on record are Hanmi Pharmaceutical, Daewoong Pharmaceutical, Yuhan Corporation, SK Bioscience, Bukwang Pharmaceutical and Embecta (Becton Dickinson spin-off). Broad incumbents are Celltrion, LG Chem Life Sciences and Novo Nordisk. Huons Global (parent) is listed as an others.

Does Huons have an API?

No public API is recorded for Huons.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NaverHuons Reports Preclinical Weight Loss Data for Oral MC4R Drug CandidateHuons reported preclinical data for its oral MC4R agonist HUC1-622 at the Obesity Society meeting, showing weight and fat reduction in obese animal models. The compound maintained activity despite AgRP and demonstrated greater selectivity for MC4R over MC1R, potentially lowering skin pigmentation risks. Huons plans initial development for rare obesity forms.NaverHuons Global's Q3 profit tumbles 54% as costs mountHuons Global reported Q3 operating profit of 9.4 billion won, down 53.9% year-over-year, while revenue rose 1.7% to 214.8 billion won. Subsidiary Huons posted an operating loss of 4.5 billion won, and the company approved a 200 won per share dividend.NaverHuons Speeds Development of Oral Treatment for Rare Obesity, With Animal Tests Confirming Weight LossHuons presented preclinical data on HUC1-622, an oral MC4R agonist, at ObesityWeek 2026, showing it reduced body weight and fat in animal models. The drug resisted AgRP and maintained signaling after dosing, with high selectivity for MC4R. Huons plans to develop it as an oral treatment to replace injectable peptide therapies.NaverHuons to Present Preclinical Data on Fibrostenotic Crohn’s Disease at UEG Week 2026Huons presented preclinical data on its TG2 inhibitor HUC1A-626 at UEG Week 2026 in Barcelona. The oral drug showed anti-fibrotic effects in cell and animal models, reducing fibrotic lesions and collagen. Huons plans to present a novel therapeutic strategy targeting the root cause of fibrostenotic Crohn's disease.NaverHUC1A-626: The Breakthrough TG2 Inhibitor for Fibrostenotic Crohn's Disease Revealed at UEG Week 2026Huons presented preclinical data on its oral TG2 inhibitor HUC1A-626 at UEG Week 2026 in Barcelona, targeting fibrotic stricturing Crohn's disease. The study showed high inhibitory efficacy and selectivity against TG2, with anti-fibrotic effects in human fibroblasts and animal models. Huons plans to develop a differentiated treatment strategy, pending future clinical trials.BusinesskoreaHuons Unveils Promising Preclinical Results for Crohn's Disease Fibrosis Drug CandidateHuons presented preclinical data on its oral TG2 inhibitor HUC1A-626 at UEG Week 2026, showing antifibrotic effects in animal studies. The drug targets intestinal fibrosis, a complication affecting half of Crohn's disease patients, and aims to be a first-in-class treatment. Clinical efficacy and safety remain to be established.NaverHuons to Exclusively Distribute Substipharm Biologics’ Japanese Encephalitis Vaccine ImojevHuons signed an exclusive domestic distribution agreement with Substipharm Biologics for the Japanese encephalitis vaccine Imojev. The live-attenuated vaccine requires only two doses for children and one for adults, contrasting with inactivated vaccines needing up to five doses. The partnership aims to strengthen Huons' vaccine portfolio and supply system.KoreajoongangdailyHuons selected for three national projects to develop new drugsHuons and three local biotech partners were selected for national projects developing new drugs for diabetic eye disease, cancer, and drug-resistant tumors. The projects involve an mRNA-lipid nanoparticle eye drop, an antibody-drug conjugate, and a subcutaneous peptide anticancer drug. The selection is part of a government-backed program with 10 projects chosen this year.KoreajoongangdailyHuons Group accelerates competitiveness through product innovationHuons Group consolidated its pharmaceutical production by merging with HuonsLifeSciences in June, and earlier merged with BioRosette to unify R&D and manufacturing. It expanded Chuncheon's health functional foods capacity by 200% to 10,000 tons annually and received Process Safety Management certification. The group aims to strengthen core manufacturing competitiveness across its healthcare businesses.MkHuons scraps Huons Lab merger amid shareholder oppositionHuons and Huons Lab have terminated their proposed merger after Huons' board voted to end the agreement following a special committee's recommendation, citing shareholder opposition to the exchange ratio and a sharp decline in Huons' share price. The committee warned that appraisal rights and potential buybacks could erode existing shareholder value. Huons will instead support Huons Lab's R&D and pursue global licensing deals.